JUN 20, 2018 07:30 AM PDT

Keynote Presentation: Supporting Precision Medicine and Clinical Research at Scale - Challenges and Opportunities

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Senior Director of Translational Genomics and Product Development, Institute Scientist, Broad Institute of MIT and Harvard
    Biography
      Niall J. Lennon, PhD, is Senior Director of Translational Genomics and Product Development with the Genomics Platform at the Broad Institute of MIT & Harvard. Niall has been working on NGS applications and technology development at the Broad for over 11 years. Most recently, Dr. Lennon oversaw the creation, certification and launch of a CLIA certified & CAP accredited laboratory within the Broad. He led the efforts to validate and implement a clinical Whole Exome sequencing test for both germline and somatic samples.
      Niall is currently an Adjunct Assistant Professor of Biomedical Engineering at Tufts University. Niall has received a Black Belt in Six Sigma for his work on process design and optimization. He also holds an executive certificate in Management and Leadership from the MIT Sloan School of Management. Niall earned a PhD in Pharmacology, and a BSc from University College Dublin, Ireland.

    Abstract:

    Precision medicine based on molecular profiling is moving from the realm of clinical utility studies towards standard of care. There remain, however, significant technological and implementation challenges that need to be addressed to ensure the widespread access to high complexity tests. These challenges include the provision of high quality, scalable assays that can be offered in clinically meaningful timeframes and at a cost that does not limit adoption. In addition, the computational and analytical environments must exist to host, compute, and deliver the increasingly large data sets created for each patient. There needs to be agreement on best practices and specifications for performance of secondary analysis tools (variant callers) across all classes of clinically meaningful variant categories. And, there needs to be education and training of a large network of variant review scientists, clinical geneticists, and molecular pathologists on variant interpretation and classification. This presentation will contemplate these challenges, highlight areas where progress has been made, and where more has yet to be done. 


    Show Resources
    You May Also Like
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    MAY 02, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 02, 2018 08:00 AM PDT
    Immunohistochemistry protocols, which utilize antibodies to visualize proteins in tissue sections, have many steps that need optimized to prevent non-specific background effects, artifacts, o...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    Loading Comments...
    Show Resources